Rare cases of Ménière's disease in children.
Classical Ménière's disease is rarely found in children and literature regarding it is scarce. In general, the frequency of Ménière's disease in children is only 0.4-7.0 per cent of that in adults. The progression pattern of Ménière's disease in children is not known well. Here, we report three cases of Ménière's disease in children less than 15 years old, treated over nine years. The three cases comprise 14- and 13-year-old boys and a nine-year-old girl. Two of the three patients initially complained only of recurrent bouts of vertigo, without any tinnitus, ear fullness or hearing impairment. In all three cases, the early pure tone audiograms showed only high tone frequency loss, regardless of subjective hearing loss, and the decrease in the hearing threshold was observed one to eight years after the dizziness attacks began. The hearing threshold was usually decreased to a level of mild or moderate hearing impairment. After diuretic treatment, vertigo was generally well controlled, and some cases showed improvement in hearing. Of the total number of patients with Ménière's disease who visited our department over nine years, 2.6 per cent (3/114) were children, and the overall incidence of Ménière's disease in children with vertigo was 2.0 per cent (3/147). In conclusion, Ménière's disease in children rarely develops and may have characteristics of high tone loss in initial audiograms.
Choung
Y H
YH
Department of Otolaryngology, Ajou University School of Medicine, Suwon, Republic of Korea. yhc@ajou.ac.kr
Park
K
K
Kim
C H
CH
Kim
H J
HJ
Kim
K
K
D000293:Adolescent; D001301:Audiometry, Pure-Tone; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D020441:Ginkgo biloba; D034381:Hearing Loss / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D008297:Male; D008575:Meniere Disease / Q000175:diagnosis / Q000188:drug therapy; D008517:Phytotherapy; D010936:Plant Extracts / Q000627:therapeutic use; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use; D014292:Trimetazidine / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D010936:Plant Extracts; D049993:Sodium Chloride Symporter Inhibitors; D014665:Vasodilator Agents; D006852:Hydrochlorothiazide; D014292:Trimetazidine